Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q2

4886.TEDINET S100PIUD
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥30.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥28.5bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥2.7bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥3.0bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥3.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥4.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥86.2bnat 2022-09-30Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥78.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥34.2bnat 2022-09-30Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥41.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥199m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥427m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥83.182022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.252022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-98.522021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-137.172021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥114m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥20m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥473m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥231m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥93m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥66m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥26m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥342m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥229m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥26m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 470
ItemContextValueUnit
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数100株
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口）
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)東京都港区浜松町２丁目11番３号
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)武田薬品工業株式会社
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)大阪市中央区道修町４丁目１－１
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)ゼリア新薬工業株式会社
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋小舟町10番11号
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)株式会社三菱ＵＦＪ銀行
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都千代田区丸の内２丁目７番１号
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行（信託口）
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)東京都中央区晴海１丁目８－12
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)山口隆
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)横浜市港北区
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)株式会社ヤマグチ
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)東京都港区三田３丁目１番10号三田マルハチビル６Ｆ
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)あいおいニッセイ同和損害保険株式会社（常任代理人　日本マスタートラスト信託銀行株式会社）
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)東京都渋谷区恵比寿１丁目28番１号（東京都港区浜松町２丁目11番３号）
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)日本生命保険相互会社（常任代理人　日本マスタートラスト信託銀行株式会社）
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)東京都千代田区丸の内１丁目６番６号（東京都港区浜松町２丁目11番３号）
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)あすか製薬ホールディングス従業員持株会
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)東京都港区芝浦２丁目５－１
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember
Original text (Japanese)単元株式数100株
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember
Original text (Japanese)同上
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)あすか製薬ホールディングス株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都港区芝浦２丁目５－１
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass